Chuikyo OKs Listing of Astellas’ AML Med, Lilly’s Verzenio and More on Nov. 20

The Central Social Insurance Medical Council, a key health ministry reimbursement panel better known as Chuikyo, on November 14 approved NHI price listing for 12 new drugs on November 20, including Astellas Pharma’s sakigake -designated acute myeloid leukemia (AML) treatment...read more